Ancient Fables for the Neobiological Age
By Brian Bergstein,
Neo.Life
| 12. 28. 2017
What “Frankenstein” and the golem tell us about the power and responsibility of science.
January 1 marks the 200th anniversary of the publication of Frankenstein, Mary Shelley’s remarkable novel about a scientist who cobbles together body parts and brings them to life in a “new species.” Because Victor Frankenstein’s project has terrible unintended consequences — he ditches his monster because it is ugly, and the creature roams the world in a destructive search for a mate — the novel can be read as a warning about messing with nature. Those sad and scary themes rear up when people use a term like “Frankenfoods” to denigrate bioengineered products.
But even if Shelley thought of the book as cautionary tale (and it’s debatablewhether she did), that isn’t a very useful cultural shorthand today, as we wrestle with the implications of gene editing, gene writing, and other technologies that give us more power than ever to manipulate biology. Caution is of course required with these technologies. But an excess of it—too much worry about unleashing Frankenstein’s monster—could be even more dangerous. Ultimately, we’re going to have...
Related Articles
By Gerry Smith, Bloomberg | 03.12.2024
When Celenise Mahmood first learned about two new gene therapies that could cure sickle cell disease, she felt a wave of relief.
Her 9-year-old son, Navid, has the inherited blood disorder. By age 5, he’d had over 30 life-saving blood...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...
By Nada Hassanein, New Jersey Monitor | 03.14.2024
The U.S. Food and Drug Administration late last year approved two breakthrough gene therapies for sickle cell disease patients. Now a new federal program seeks to make these life-changing treatments available to patients with low incomes — and it could...
By Rob Stein, NPR | 03.07.2024
A big federal research project aimed at reducing racial disparities in genetic research has unveiled the program's first major trove of results.
"This is a huge deal," says Dr. Joshua Denny, who runs the All of Us program at...